OncoSec Medical CEO Punit Dhillon to Host Live Webinar to Provide Corporate Update and 2015 Outlook
March 17 2015 - 6:00AM
Business Wire
OncoSec Medical Inc. (“OncoSec”) (OTCQB: ONCS), a company
developing DNA-based intratumoral cancer immunotherapies, today
announced it will provide a comprehensive corporate update and
Q&A session for investors and the general public during a
webinar starting at 9:30 AM PDT on Monday, March 23, 2015.
Punit Dhillon, President and CEO, will host the webinar to
provide an engaging, educational discussion regarding the company
and its outlook for the upcoming year. Attendees will hear
first-hand from the CEO as he shares updates on several pertinent
topics, including: clinical trials timeline, research activities,
development of new electroporation devices, financial updates, and
current market opportunity in the cancer immunotherapy
landscape.
The company will also address questions from the public during
the webinar’s Q&A session. OncoSec encourages people to submit
their questions prior to the webinar via OncoSec’s social media
channels: Twitter (https://twitter.com/oncosec) and Facebook
(https://www.facebook.com/oncosecmedical).
To register for the event, please click on the following link
at any time prior to the webinar:
https://attendee.gotowebinar.com/register/4040606641159991809.
Please register at least 10 minutes prior to the start of the
presentation to ensure timely access. After registering, you will
receive a confirmation email containing information about joining
the webinar.
For technical assistance, please contact Go To Webinar at
855-352-9002. For those unable to attend to the live webinar, an
archive version will be available for 90 days on OncoSec’s website:
http://www.oncosec.com.
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing
its investigational ImmunoPulse intratumoral cancer immunotherapy.
OncoSec’s core technology is designed to enhance the local delivery
and uptake of DNA IL-12 and other DNA-based immune-targeting
agents. Clinical studies of ImmunoPulse have demonstrated an
acceptable safety profile and preliminary evidence of anti-tumor
activity in the treatment of various skin cancers, as well as the
potential to initiate a systemic immune response limiting the
systemic toxicities associated with other treatments. OncoSec’s
lead program evaluating ImmunoPulse for the treatment of metastatic
melanoma is currently in Phase II development, and is being
conducted in collaboration with several prominent academic medical
centers. As the company continues to evaluate ImmunoPulse in its
current indications, it is also focused on identifying and
developing new immune-targeting agents, investigating additional
tumor indications, and evaluating combination-based immunotherapy
approaches. For more information, please visit www.oncosec.com.
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such “forward-looking statements.”
Forward-looking statements are based on management’s current
preliminary expectations and are subject to risks and
uncertainties, which may cause our results to differ materially and
adversely from the statements contained herein. Some of the
potential risks and uncertainties that could cause actual results
to differ from those predicted include our ability to raise
additional funding, our ability to acquire, develop or
commercialize new products, uncertainties inherent in pre-clinical
studies and clinical trials, unexpected new data, safety and
technical issues, competition, and market conditions. These and
additional risks and uncertainties are more fully described in
OncoSec Medical’s filings with the Securities and Exchange
Commission. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
Medical disclaims any obligation to update any forward-looking
statements to reflect new information, events or circumstances
after the date they are made, or to reflect the occurrence of
unanticipated events.
OncoSec Medical Inc.Investor Relations:Jordyn Kopin,
855-662-6732investors@oncosec.comorMedia Relations:Mary Marolla,
855-662-6732media@oncosec.com
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Mar 2024 to Apr 2024
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Apr 2023 to Apr 2024